An interventional study of mHealth in Intellectual Disabilities (F70-F79), Down Syndrome (DS) and Autism Disorder, sponsored by University of Seville. Recruiting at 1 site in Spain. Open to participants aged 4 Years to 30 Years. Per ClinicalTrials.gov, last updated 2025-08-07.
Sponsored by University of Seville · Not applicable, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 36 studies in Down Syndrome with a site in Spain — 9 open to participants now, 9 under way, 1 of them phase 3. Down Syndrome · Spain.
Among the 36 studies in Down Syndrome with a site in Spain, this one is the 7th largest by planned enrollment of the 18 interventional ones that give a count, is one of 4 that started in 2024, is one of 10 with no phase, and was the 31st registered.
439 studies on the registry are indexed under Down Syndrome; 99 are open to participants now.
Browse Down Syndrome studies →9 of the 36 studies in Down Syndrome with a site in Spain are open now. Recruiting first, the newest first:
Alnylam Pharmaceuticals · Sites in Spain, United States, United Kingdom
Ages 40–55
Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau · Sites in Spain
Ages 40+
Aelis Farma · Sites in Spain, France, Italy
Ages 16–32
University of Seville · Sites in Spain
Ages 1 mo–18 mo
AC Immune SA · Sites in Spain, United States, United Kingdom
Ages 35–85
A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →
Of the 74 Down Syndrome studies recruiting now, 14 (19%) set no upper age limit and 57 (77%) stop at 75 or younger; 60 take children under 18; 19 take healthy volunteers.
This study: 4 Years to 30 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
36 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 6 · Phase 3 1
First in 2009; this study’s year is marked. 4 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 60 is above the median of 38 across 287 interventional studies indexed under Down Syndrome.
Median enrollment 58 across the 18 interventional studies, 113 across the 18 observational. Of the 20 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
14 of 36 have an industry lead sponsor. The 10 most frequent:
University of Seville is the lead sponsor of 131 studies on the registry; 39 are open to participants now.
University of Seville has 4 studies filed under Down Syndrome — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 36 studies in Down Syndrome with a site in Spain, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
IDHEApp will implement various educational technology tools and work with the families, teachers and caregivers to increase physical activity (PA) and improve healthy eating. Due to the current COVID-19 pandemic restrictions, the use of innovative digital technology can contribute not just to distance learning but also to support families and students in remote. However, both healthy habits and technologies are insufficiently addressed in the population with IDD. These needs are in line with the following objectives of the Erasmus+ programme: a) Inclusion and diversity in all fields of education, training, youth and sport; b) Addressing digital transformation through development of digital readiness, resilience and capacity, and c) Encouraging the participation in sport and physical activity.
Educators will find innovative possibilities and the right instruments that will enable them to fulfil their potential through innovative online education \& learning \& training skills module for lifestyle promotion and others available on the app. Furthermore, mentors and others health professionals (e.g., nursing etc.) will be equipped with knowledge and skills on how to use the app to teach practical skills for PA enhancement in an evidence-based way. Consequently, this project will contribute to [specific objectives - SO]:
- Raise awareness of the importance of healthy and active living among young Europeans with intellectual disabilities.
Different workshops and bigger events (i.e., international conference), together with the involvement of numerous participants from the institutions of this consortium will be ensured. Further, a sensitized community will participate through the social networks and the website itself, in the proposed activities.
- Provide digital resources and tools to the partner entities of the exchange to improve lifestyle of young people with intellectual disabilities.
Best Practices to provide high quality, inclusive digital health education with the best educational technology tools and methodology. A website, a mobile app and different electronic guidelines will be delivered.
- Analyze the current state of use and acceptance of technologies as support in the management of health in adolescent with intellectual disabilities.
Young individuals with intellectual disabilities (ID) often exhibit significant challenges in maintaining healthy lifestyle habits, particularly concerning physical activity and nutrition. Current evidence indicates that individuals with ID participate in significantly lower levels of physical activity compared to their typically developing peers, with a substantial proportion not meeting established physical activity guidelines. A recent literature review highlights that adults with ID often exhibit elevated levels of sedentary behaviour, which is associated with increased prevalence of obesity, multimorbidity, and metabolic syndrome. The review emphasizes that sedentary behaviour may contribute to the poor health commonly observed in this population. In addition to insufficient physical activity, dietary patterns among young people with intellectual disabilities often skew towards processed foods high in sugar and fat, further compounding their overall health risks.
Addressing these unhealthy behaviors is critical, as they significantly impact the overall well-being of young individuals with ID. Various strategies have been developed to manage and improve lifestyle-related health outcomes in this population. Interventions focusing on lifestyle modifications commonly emphasize structured exercise programs and nutritional education, aiming to promote sustainable, positive health behaviors. However, traditional intervention approaches often face significant challenges in effectively engaging young people with ID, limiting their long-term impact.
In recent years, mobile health (mHealth) interventions have emerged as innovative tools that leverage technology to enhance physical activity and nutritional habits among young individuals with ID. These digital solutions have demonstrated efficacy in promoting behaviour change through interactive, user-friendly platforms, offering an especially attractive alternative for populations that often encounter barriers in traditional health intervention contexts. Existing studies indicate that mHealth applications can facilitate behaviour modification by providing tailored feedback, goal-setting functionalities, and motivational elements, such as gamification.
Despite the significant promise of mHealth interventions in promoting healthier behaviors, evidence regarding their efficacy specifically among individuals with ID remains scarce. Most existing studies have focused on the general population, with limited research adapting these technologies to the cognitive, social, and communication needs of individuals with ID. Several barriers may limit the effectiveness and scalability of mHealth solutions in this population, including difficulties with digital literacy, limited accessibility features in current applications, lack of caregiver or support system involvement, and challenges related to sustained engagement over time. Consequently, there is a critical need for rigorously designed studies that not only evaluate the effectiveness of mHealth interventions for young individuals with ID, but also systematically address the unique barriers this population faces in accessing and benefiting from such technological innovations. Additionally, a significant gap persists in research that adequately considers the diverse manifestations of intellectual disability (e.g., such as Down syndrome and other neurodevelopmental conditions), leading to an incomplete understanding of the true potential and limitations of mHealth solutions across the full spectrum of cognitive and functional profiles. To date, there are only a limited number of studies specifically exploring the use of mHealth interventions to promote physical activity among individuals with ID. Various initiatives demonstrate the feasibility of integrating digital tools to promote physical activity among individuals with ID, they also present notable limitations. These include small sample sizes and a focus on specific subgroups, which hinder the generalizability of their findings. Furthermore, many of these studies predominantly involved adult participants, leaving a significant gap in research related to younger populations, where early intervention is crucial for fostering long-term healthy behaviors. In response to these gaps, our study aims to conduct a randomized controlled trial (RCT) to assess the effectiveness of mHealth interventions in improving physical activity and nutrition in young individuals with ID. By addressing the unique barriers this population faces in engaging with digital health solutions, our research seeks to provide a more comprehensive and inclusive understanding of how mHealth interventions can positively impact health outcomes during this critical developmental stage. Through this approach, we aim to identify effective strategies for promoting sustainable behavior change in young individuals with ID.
Methods Study Design This study followed a multicenter, randomized controlled trial (RCT) design and was conducted in two European cities: Rome (Italy) and Rijeka (Croatia). Participants were stratified by site and randomly assigned to either an experimental group, which received a gamified mHealth-based intervention aimed at improving physical activity and eating habits, or to a control group, which continued with their usual routines without intervention. In Rome, the sample included only individuals with Down syndrome, while in Rijeka the participants had mild to moderate intellectual disabilities without comorbid Down syndrome. Randomization was carried out using a computer-generated sequence, and the allocation was concealed until the moment of assignment. All procedures complied with the ethical standards of the institutional research committees and adhered to the Helsinki Declaration. Informed consent was obtained from participants or their legal representatives.
439 studies on the registry are indexed under Down Syndrome; 99 are open to participants now.
This study's planned enrollment of 60 is above the median of 38 across 287 interventional studies indexed under Down Syndrome.
Browse Down Syndrome studies →University of Seville is the lead sponsor of 131 studies on the registry; 39 are open to participants now.
Compared within Down Syndrome, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Intellectual Disability. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The intervention was carried out over a period of 8 consecutive weeks and was delivered through a mobile application specifically developed for this project, called IDHEApp, which incorporated gamification elements to enhance user engagement and motivation. Participants in the experimental group received a structured mHealth-based program aimed at promoting healthier behaviors in three primary domains: physical activity, sedentary behavior reduction, and dietary improvement. Objective data on physical activity and sedentary behavior were collected using a smartwatch device (Fitbit Versa 3), which was worn by all participants in both the experimental and control groups throughout the study. However, only participants in the experimental group received a daily personalized behavioral challenge targeting one of the following domains: 1. Increasing physical activity (e.g., "Walk an additional 1,000 steps today"); 2. Reducing sedentary behavior (e.g., "Stand up and move for at least 5 minu
Behavioral: mHealth
The control group, in contrast, received no intervention and continued with their usual routines without additional support or monitoring beyond the baseline and post-intervention assessments.
The intervention was carried out over a period of 8 consecutive weeks and was delivered through a mobile application specifically developed for this project, called IDHEApp, which incorporated gamification elements to enhance user engagement and motivation. Participants in the experimental group received a structured mHealth-based program aimed at promoting healthier behaviors in three primary domains: physical activity, sedentary behavior reduction, and dietary improvement. Objective data on physical activity and sedentary behavior were collected using a smartwatch device (Fitbit Versa 3), which was worn by all participants in both the experimental and control groups throughout the study. However, only participants in the experimental group received a daily personalized behavioral challenge targeting one of the following domains: 1. Increasing physical activity (e.g., "Walk an additional 1,000 steps today"); 2. Reducing sedentary behavior (e.g., "Stand up and move for at least 5 minut
Daily step count
was recorded as a proxy for general physical activity volume. This variable captured the total number of steps taken each day
Time frame: From enrollment to the end of treatment at 8 weeks
light activity
Periods of low-intensity movement such as slow walking or light household tasks,
Time frame: From enrollment to the end of treatment at 8 weeks
Sitting time
Total duration per day spent seated, used as a direct indicator of sedentary behavior
Time frame: From enrollment to the end of treatment at 8 weeks
Total sleep time
Sum of all sleep periods in a given night
Time frame: From enrollment to the end of treatment at 8 weeks
Children's Physical Activity Questionnaire (CPAQ)
To assess self-reported physical activity and sedentary behavior, the Children's Physical Activity Questionnaire (CPAQ) was administered to participants with the support of caregivers or facilitators when necessary. The CPAQ is a semi-structured, interviewer-administered instrument designed to evaluate the typical weekly frequency and duration of different activity types over the previous 7 days. Although originally developed for children, the CPAQ has been successfully adapted and validated in populations with intellectual and developmental disabilities due to its straightforward language and structure (McQueen et al., 2024).
Time frame: From enrollment to the end of treatment at 8 weeks
Sleep quality
Pittsburgh Sleep Quality Index (PSQI) A widely used instrument that assesses sleep quality over a one-month interval. It consists of 19 items grouped into 7 components: a) Subjective sleep quality, b) Sleep latency (time to fall asleep), c) Sleep duration, d) Habitual sleep efficiency, e) Sleep disturbances, f) Use of sleep medication, g) Daytime dysfunction. Each component is scored from 0 to 3, and the sum yields a global score (0-21), with higher scores indicating poorer sleep quality. A global score \>5 is considered indicative of poor sleep.
Time frame: From enrollment to the end of treatment at 8 weeks
health-related quality of life (HRQoL)
To assess health-related quality of life (HRQoL) in individuals with intellectual disabilities, the study employed the Quality of Life Inventory - Intellectual Disability (QI-Disability). This is a validated, condition-specific instrument designed to capture the multidimensional nature of quality of life in individuals with cognitive impairments, including those with mild to severe intellectual disability (Downs et al., 2019). The QI-Disability evaluates six core domains of HRQoL: a) Physical Health, b) Negative Emotions, c) Positive Emotions, d) Social Participation, e) Interpersonal Relationships and f) Independence. Each item is rated on a 4-point Likert scale ranging from "never" to "always," with higher scores indicating a more favorable quality of life in the respective domain. The QI-Disability has shown robust psychometric properties, including high internal consistency and construct validity, in populations with intellectual disabilities (Downs et al., 2019). Importantly, it
Time frame: From enrollment to the end of treatment at 8 weeks
Plan to share: Yes — Individual Participant Data (IPD) that will be shared include de-identified data related to primary and secondary outcomes, such as measures of physical activity (e.g., step counts, activity duration), sleep duration, and nutrition-related behaviors. Only IPD used in the results publication will be shared. No personally identifiable information will be included. Data will be shared in accordance with applicable ethical approvals and data protection regulations. Due to the vulnerability of the study population, access to the IPD will be limited to qualified researchers upon reasonable request and subject to a data sharing agreement that ensures confidentiality and appropriate data use.
Supporting information: Study protocol
Time frame: De-identified individual participant data (IPD) will be made available beginning 6 months after publication of the primary results and will remain available for a period of 5 years following publication.
Access criteria: Access to the de-identified individual participant data (IPD) will be granted to qualified researchers affiliated with academic or non-profit institutions for the purpose of secondary analyses related to intellectual disabilities, mHealth interventions, or health promotion. Requests must include a detailed research proposal, ethical approval or exemption, and a signed data use agreement. All requests will be reviewed by the study steering committee to ensure appropriate use and compliance with data protection regulations.
No publications or documents are linked to this record.
Started Jan 2024 (actual). Primary completion is estimated for Sep 2025, 20 months after the start.
Of 163 non-industry interventional studies with no phase under Down Syndrome, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 33. This study's planned 20 months is above that.
Counting every sponsor, half of 165 studies reached it within 11 months; a quarter within 3 and three quarters within 35.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.